Q-omics provides the consensus-scored GLT1D1 profile across patient tissues and cancer cell-line models. GLT1D1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, GLT1D1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, GLT1D1 RNA expression shows 20,689 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, THCA, and GBM as cancer lineages where GLT1D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLT1D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLT1D1 survival associations across molecular data types. GLT1D1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLT1D1 RNA expression–survival associations across cancer types. High GLT1D1 expression shows unfavorable associations in STAD and KIRC, but favorable associations in UVM, THCA, HNSC and ESCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for GLT1D1 RNA expression.
This table summarizes GLT1D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GLT1D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLT1D1 shows lower tumor expression in UCEC, LUAD, LUSC, BRCA and CHOL and higher tumor expression in THCA. The THCA box plot shows higher GLT1D1 RNA expression in tumor versus normal tissue (log2 FC = +2.557, t-test p < 0.001).
This table shows molecular features associated with GLT1D1 in patient tissues and cancer cell lines. In patient samples, GLT1D1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GLT1D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LUNG_SCLC.
